Editas Medicine (EDIT) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

EDIT Stock Forecast

Editas Medicine stock forecast is as follows: an average price target of $12.85 (represents a 433.20% upside from EDIT’s last price of $2.41) and a rating consensus of 'Buy', based on 12 wall street analysts offering a 1-year stock forecast.

EDIT Price Target

The average price target for Editas Medicine (EDIT) is $12.85 based on 1-year price targets from 12 Wall Street analysts in the past 3 months, with a price target range of $35.00 to $5.00. This represents a potential 433.20% upside from EDIT's last price of $2.41.

EDIT Analyst Ratings

Buy

According to 12 Wall Street analysts, Editas Medicine's rating consensus is 'Buy'. The analyst rating breakdown for EDIT stock is 0 'Strong Buy' (0.00%), 6 'Buy' (50.00%), 6 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Editas Medicine Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Nov 05, 2024	Gena Wang	Barclays	$5.00	$3.12	60.26%	107.47%
Oct 23, 2024	Yanan Zhu	Wells Fargo	$9.00	$3.29	173.56%	273.44%
Oct 22, 2024	Joel Beatty	Robert W. Baird	$10.00	$3.29	203.95%	314.94%
Aug 08, 2024	Joon Lee	Truist Financial	$12.00	$4.24	183.02%	397.93%
Aug 08, 2024	Greg Harrison	Bank of America Securities	$15.00	$4.21	256.72%	522.41%
May 30, 2024	Liisa Bayko	Evercore ISI	$7.00	$5.10	37.25%	190.46%
May 09, 2024	Matthew Harrison	Morgan Stanley	$7.00	$5.04	39.03%	190.46%
Sep 28, 2023	Dae Gon Ha	Stifel Nicolaus	$17.00	$6.92	145.66%	605.39%
Dec 13, 2022	-	Citigroup	$11.00	$9.96	10.44%	356.43%
Nov 18, 2022	-	Morgan Stanley	$8.00	$10.63	-24.78%	231.95%

Row per page

Go to

The latest Editas Medicine stock forecast, released on Nov 05, 2024 by Gena Wang from Barclays, set a price target of $5.00, which represents a 60.26% increase from the stock price at the time of the forecast ($3.12), and a 107.47% increase from EDIT last price ($2.41).

Editas Medicine Price Target by Period

	1M	3M	12M
# Anlaysts	3	3	7
Avg Price Target	$8.00	$8.00	$9.29
Last Closing Price	$2.41	$2.41	$2.41
Upside/Downside	231.95%	231.95%	285.48%

In the current month, the average price target of Editas Medicine stock is $8.00, according to 3 Wall Street analysts offering twelve months forecast. The average price target represents a 231.95% increase as opposed to Editas Medicine's last price of $2.41. This month's average price target is down 0.00% compared to last quarter, and down -13.89% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Nov 06, 2024	Evercore ISI	-	Outperform	Upgrade
Nov 05, 2024	Oppenheimer	Perform	Perform	Hold
Nov 05, 2024	Barclays	Mixed	Mixed	Hold
Nov 04, 2024	RBC Capital	Sector Perform	Sector Perform	Hold
Oct 23, 2024	Wells Fargo	Sector Perform	Sector Perform	Hold
Oct 23, 2024	Wells Fargo	Overweight	Overweight	Hold
Aug 08, 2024	Bank of America Securities	-	Buy	Upgrade
Jun 18, 2024	Oppenheimer	Buy	Buy	Hold
May 08, 2024	Morgan Stanley	Underweight	Equal-Weight	Upgrade
May 08, 2024	Citigroup	Buy	Buy	Hold

Row per page

Go to

Editas Medicine's last stock rating was published by Evercore ISI on Nov 06, 2024. The company Upgrade its EDIT rating from "null" to "Outperform".

Editas Medicine Financial Forecast

Editas Medicine Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$9.85M	$6.54M	$42.00K	$6.36M	$6.77M	$12.47M	$6.20M	$379.00K	$6.50M	$11.42M	$62.84M	$10.75M	$5.72M	$12.28M	$3.85M
Avg Forecast	$103.21K	$97.35K	$91.83K	$86.61K	$3.34M	$3.10M	$2.53M	$2.52M	$30.73M	$3.93M	$4.78M	$11.14M	$3.70M	$3.70M	$4.17M	$3.29M	$3.66M	$4.39M	$4.29M	$3.85M	$4.64M	$4.74M	$6.03M	$5.83M	$5.64M	$6.36M	$6.34M	$6.72M	$44.61M	$4.76M
High Forecast	$258.83K	$244.14K	$230.28K	$217.21K	$8.37M	$7.76M	$6.35M	$4.06M	$69.07M	$9.85M	$4.78M	$11.14M	$15.40M	$3.70M	$10.46M	$8.24M	$9.17M	$4.39M	$4.29M	$3.85M	$4.64M	$4.74M	$6.03M	$5.83M	$5.64M	$6.36M	$6.34M	$6.72M	$44.61M	$4.76M
Low Forecast	$1.57K	$1.48K	$1.40K	$1.32K	$50.90K	$47.18K	$38.61K	$812.94K	$76.99K	$59.89K	$4.78M	$11.14M	$826.63K	$3.70M	$63.60K	$50.08K	$55.76K	$4.39M	$4.29M	$3.85M	$4.64M	$4.74M	$6.03M	$5.83M	$5.64M	$6.36M	$6.34M	$6.72M	$44.61M	$4.76M
# Analysts	3	3	3	3	4	4	4	6	12	6	7	4	9	4	6	4	3	7	4	3	4	7	4	4	6	3	3	3	2	2
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.00%	1.79%	0.01%	1.48%	1.76%	2.69%	1.31%	0.06%	1.12%	2.02%	9.89%	1.70%	0.85%	0.28%	0.81%

Editas Medicine's average Quarter revenue forecast for Jun 23 based on 6 analysts is $4.17M, with a low forecast of $63.60K, and a high forecast of $10.46M. EDIT's average Quarter revenue forecast represents a -57.65% decrease compared to the company's last Quarter revenue of $9.85M (Mar 23).

Editas Medicine EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	3	3	3	3	4	4	4	6	12	6	7	4	9	4	6	4	3	7	4	3	4	7	4	4	6	3	3	3	2	2
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	$-45.02M	$-40.29M	$-50.96M	$-63.45M	$-55.92M	$-52.64M	$-49.19M	$-39.92M	$-37.89M	$-54.07M	$-55.56M	$-61.32M	$8.93M	$-23.29M	$-38.48M	$-38.63M	$-33.89M
Avg Forecast	$-103.21K	$-97.35K	$-91.83K	$-86.61K	$-3.34M	$-3.10M	$-2.53M	$-2.52M	$-30.73M	$-3.93M	$-4.78M	$-62.38M	$-3.70M	$-3.70M	$-4.17M	$-56.71M	$-58.22M	$-4.39M	$-4.29M	$-51.56M	$-4.64M	$-4.74M	$-6.03M	$-45.67M	$-5.64M	$-6.36M	$-6.34M	$-43.36M	$-44.61M	$-4.76M
High Forecast	$-1.57K	$-1.48K	$-1.40K	$-1.32K	$-50.90K	$-47.18K	$-38.61K	$-812.94K	$-76.99K	$-59.89K	$-4.78M	$-49.91M	$-826.63K	$-3.70M	$-63.60K	$-45.37M	$-46.58M	$-4.39M	$-4.29M	$-41.25M	$-4.64M	$-4.74M	$-6.03M	$-36.54M	$-5.64M	$-6.36M	$-6.34M	$-34.69M	$-44.61M	$-4.76M
Low Forecast	$-258.83K	$-244.14K	$-230.28K	$-217.21K	$-8.37M	$-7.76M	$-6.35M	$-4.06M	$-69.07M	$-9.85M	$-4.78M	$-74.86M	$-15.40M	$-3.70M	$-10.46M	$-68.06M	$-69.87M	$-4.39M	$-4.29M	$-61.87M	$-4.64M	$-4.74M	$-6.03M	$-54.80M	$-5.64M	$-6.36M	$-6.34M	$-52.03M	$-44.61M	$-4.76M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	12.16%	9.66%	0.90%	1.09%	12.73%	12.27%	0.95%	8.60%	8.00%	8.97%	1.22%	10.87%	-1.40%	3.68%	0.89%	0.87%	7.11%

6 analysts predict EDIT's average Quarter EBITDA for Dec 20 to be $-5.64M, with a high of $-5.64M and a low of $-5.64M. This is -163.22% lower than Editas Medicine's previous annual EBITDA (Sep 20) of $8.93M.

Editas Medicine Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	3	3	3	3	4	4	4	6	12	6	7	4	9	4	6	4	3	7	4	3	4	7	4	4	6	3	3	3	2	2
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	$-45.02M	$-40.29M	$-45.57M	$-55.03M	$-53.93M	$-52.67M	$-50.28M	$-41.44M	$-39.08M	$-55.26M	$-56.73M	$-62.50M	$7.82M	$-23.57M	$-37.72M	$-37.77M	$-32.94M
Avg Forecast	$-35.69M	$-35.78M	$-35.80M	$-40.72M	$-51.60M	$-51.97M	$-54.26M	$-54.99M	$-27.34M	$-61.62M	$-58.07M	$-64.99M	$-49.00M	$-47.44M	$-63.26M	$-59.08M	$-60.42M	$-70.20M	$-66.53M	$-53.71M	$-58.62M	$-66.91M	$-67.79M	$-46.63M	$-62.56M	$-51.53M	$-64.66M	$-42.50M	$4.12M	$-58.13M
High Forecast	$10.00M	$10.03M	$10.03M	$11.41M	$14.46M	$14.56M	$15.20M	$-41.24M	$30.52M	$17.26M	$16.27M	$-51.99M	$19.79M	$13.29M	$17.72M	$-47.27M	$-48.34M	$-70.20M	$-66.53M	$-42.97M	$-58.62M	$-66.91M	$-67.79M	$-37.30M	$-62.56M	$-51.53M	$-64.66M	$-34.00M	$4.12M	$-58.13M
Low Forecast	$-105.65M	$-105.92M	$-105.97M	$-120.54M	$-152.74M	$-153.82M	$-160.61M	$-59.84M	$-66.76M	$-182.40M	$-171.90M	$-77.99M	$-70.67M	$-140.42M	$-187.25M	$-70.90M	$-72.51M	$-70.20M	$-66.53M	$-64.45M	$-58.62M	$-66.91M	$-67.79M	$-55.95M	$-62.56M	$-51.53M	$-64.66M	$-51.00M	$4.12M	$-58.13M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.95%	0.64%	0.77%	0.91%	0.77%	0.79%	0.94%	0.71%	0.58%	0.82%	1.22%	1.00%	-0.15%	0.36%	0.89%	-9.18%	0.57%

Editas Medicine's average Quarter net income forecast for Dec 20 is $-62.56M, with a range of $-62.56M to $-62.56M. EDIT's average Quarter net income forecast represents a -900.05% decrease compared to the company's last Quarter net income of $7.82M (Sep 20).

Editas Medicine SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	3	3	3	3	4	4	4	6	12	6	7	4	9	4	6	4	3	7	4	3	4	7	4	4	6	3	3	3	2	2
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	$14.99M	$17.20M	$23.01M	$17.98M	$16.24M	$16.94M	$19.55M	$16.53M	$16.18M	$22.03M	$21.45M	$15.79M	$19.94M	$14.08M	$17.77M	$16.92M	$15.73M
Avg Forecast	$234.28K	$220.99K	$208.44K	$196.61K	$7.58M	$7.03M	$5.75M	$5.72M	$69.76M	$8.92M	$10.85M	$25.29M	$8.39M	$8.41M	$9.47M	$7.46M	$8.30M	$9.97M	$9.74M	$8.75M	$10.54M	$10.76M	$13.68M	$13.22M	$12.81M	$14.43M	$14.38M	$15.27M	$101.27M	$10.82M
High Forecast	$587.53K	$554.19K	$522.73K	$493.06K	$19.01M	$17.62M	$14.42M	$9.23M	$156.80M	$22.36M	$10.85M	$25.29M	$34.96M	$8.41M	$23.75M	$18.70M	$20.82M	$9.97M	$9.74M	$8.75M	$10.54M	$10.76M	$13.68M	$13.22M	$12.81M	$14.43M	$14.38M	$15.27M	$101.27M	$10.82M
Low Forecast	$3.57K	$3.37K	$3.17K	$3.00K	$115.54K	$107.11K	$87.64K	$1.85M	$174.76K	$135.94K	$10.85M	$25.29M	$1.88M	$8.41M	$144.36K	$113.68K	$126.58K	$9.97M	$9.74M	$8.75M	$10.54M	$10.76M	$13.68M	$13.22M	$12.81M	$14.43M	$14.38M	$15.27M	$101.27M	$10.82M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1.78%	1.82%	3.09%	2.17%	1.63%	1.74%	2.23%	1.57%	1.50%	1.61%	1.62%	1.23%	1.38%	0.98%	1.16%	0.17%	1.45%

Editas Medicine's average Quarter SG&A projection for Dec 23 is $8.39M, based on 9 Wall Street analysts, with a range of $1.88M to $34.96M. The forecast indicates a -43.99% fall compared to EDIT last annual SG&A of $14.99M (Sep 23).

Editas Medicine EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	3	3	3	3	4	4	4	6	12	6	7	4	9	4	6	4	3	7	4	3	4	7	4	4	6	3	3	3	2	2
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.00	$-0.00	$-0.66	$-0.80	$-0.78	$-0.77	$-0.73	$-0.61	$-0.57	$-0.81	$-0.86	$-1.00	$0.13	$-0.43	$-0.69	$-0.74	$-0.66
Avg Forecast	$-0.43	$-0.43	$-0.43	$-0.49	$-0.63	$-0.63	$-0.66	$-0.67	$-0.33	$-0.75	$-0.70	$-0.63	$-0.59	$-0.58	$-0.77	$-0.78	$-0.79	$-0.85	$-0.81	$-0.78	$-0.71	$-0.81	$-0.82	$-0.74	$-0.76	$-0.63	$-0.79	$-0.79	$0.05	$-0.71
High Forecast	$0.12	$0.12	$0.12	$0.14	$0.18	$0.18	$0.18	$-0.50	$0.37	$0.21	$0.20	$0.18	$0.24	$0.16	$0.21	$0.22	$0.22	$-0.85	$-0.81	$-0.78	$-0.71	$-0.81	$-0.82	$-0.74	$-0.76	$-0.63	$-0.79	$-0.79	$0.05	$-0.71
Low Forecast	$-1.28	$-1.28	$-1.28	$-1.46	$-1.85	$-1.86	$-1.95	$-0.73	$-0.81	$-2.21	$-2.08	$-1.85	$-0.86	$-1.70	$-2.27	$-2.32	$-2.33	$-0.85	$-0.81	$-0.78	$-0.71	$-0.81	$-0.82	$-0.74	$-0.76	$-0.63	$-0.79	$-0.79	$0.05	$-0.71
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00%	0.00%	0.84%	1.01%	0.91%	0.95%	0.93%	0.86%	0.70%	0.98%	1.16%	1.32%	-0.21%	0.55%	0.88%	-14.80%	0.93%

According to 6 Wall Street analysts, Editas Medicine's projected average Quarter EPS for Dec 20 is $-0.76, with a low estimate of $-0.76 and a high estimate of $-0.76. This represents a -684.62% decrease compared to EDIT previous annual EPS of $0.13 (Sep 20).

Editas Medicine Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
ALLO	Allogene Therapeutics	$2.05	$29.00	1314.63%	Buy
NTLA	Intellia Therapeutics	$13.12	$115.90	783.38%	Buy
PRME	Prime Medicine	$2.99	$17.25	476.92%	Buy
EDIT	Editas Medicine	$2.41	$12.85	433.20%	Buy
VERV	Verve Therapeutics	$4.55	$19.00	317.58%	Buy
SANA	Sana Bio	$2.53	$8.00	216.21%	Buy
BEAM	Beam Therapeutics	$24.49	$58.50	138.87%	Buy
CRSP	CRISPR Therapeutics	$47.26	$101.46	114.68%	Buy
CRBU	Caribou Biosciences	$1.96	$3.00	53.06%	Buy
DNA	Ginkgo Bioworks	$6.36	$7.34	15.41%	Buy
VRTX	Vertex Pharmaceuticals	$451.23	$403.92	-10.48%	Buy

EDIT Forecast FAQ

Is Editas Medicine a good buy?

Yes, according to 12 Wall Street analysts, Editas Medicine (EDIT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 50.00% of EDIT's total ratings.

What is EDIT's price target?

Editas Medicine (EDIT) average price target is $12.85 with a range of $5 to $35, implying a 433.20% from its last price of $2.41. The data is based on 12 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Editas Medicine stock go up soon?

According to Wall Street analysts' prediction for EDIT stock, the company can go up by 433.20% (from the last price of $2.41 to the average price target of $12.85), up by 1352.28% based on the highest stock price target, and up by 107.47% based on the lowest stock price target.

Can Editas Medicine stock reach $4?

EDIT's average twelve months analyst stock price target of $12.85 supports the claim that Editas Medicine can reach $4 in the near future.

What is Editas Medicine's current price target trend?

3 Wall Street analysts forecast a $8 price target for Editas Medicine (EDIT) this month, up 231.95% from its last price of $2.41. Compared to the last 3 and 12 months, the average price target increased by 231.95% and increased by 285.48%, respectively.

What are Editas Medicine's analysts' financial forecasts?

Editas Medicine's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $11.49M (high $26.55M, low $949.64K), average EBITDA is $-11.487M (high $-950K, low $-26.551M), average net income is $-213M (high $2.98M, low $-527M), average SG&A $26.07M (high $60.27M, low $2.16M), and average EPS is $-2.58 (high $0.0361, low $-6.389). EDIT's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $379K (high $950.45K, low $5.78K), average EBITDA is $-379K (high $-5.776K, low $-950K), average net income is $-148M (high $41.47M, low $-438M), average SG&A $860.33K (high $2.16M, low $13.11K), and average EPS is $-1.794 (high $0.503, low $-5.311).

Did the EDIT's actual financial results beat the analysts' financial forecasts?

Based on Editas Medicine's last annual report (Dec 2022), the company's revenue was $19.71M, beating the average analysts forecast of $16.19M by 21.74%. Apple's EBITDA was $-226M, beating the average prediction of $-118M by 90.74%. The company's net income was $-204M, missing the average estimation of $-251M by -18.54%. Apple's SG&A was $70.7M, beating the average forecast of $36.76M by 92.36%. Lastly, the company's EPS was $-2.98, missing the average prediction of $-3.232 by -7.78%. In terms of the last quarterly report (Mar 2023), Editas Medicine's revenue was $9.85M, beating the average analysts' forecast of $3.29M by 199.87%. The company's EBITDA was $-50.961M, missing the average prediction of $-56.713M by -10.14%. Editas Medicine's net income was $-45.567M, missing the average estimation of $-59.083M by -22.88%. The company's SG&A was $23.01M, beating the average forecast of $7.46M by 208.54%. Lastly, the company's EPS was $-0.66, missing the average prediction of $-0.784 by -15.83%